Pfizer is touting new clinical trial data that shows its inhaled version of insulin -- Exubera -- works just as well as the injectable kind and was well tolerated by patients over a period of two years. The results were released at a meeting of the American Diabetes Association. Pfizer believes that an inhaled version of insulin will offer higher compliance rates. Pfizer is developing the experimental drug with Sanofi-Aventis and Nektar Therapeutics. The FDA is expected to take action on their drug application by October.
- read this article from TheStreet.com for more